TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01329965
Drug: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
Study: NCT00788424
Drug: AS101 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% AS101 Cream or Placebo cream, twice a day for 12 weeks
Study: NCT00826280
Drug: overencapsulated caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00826280
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02472353
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care treatment with doxorubicin
Study: NCT04587713
Drug: TD-1473 [Tablet A]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD-1473 \[Tablet A\] (1 Tablet = Dose A) proposed commercial tablet formulation
Study: NCT04587713
Drug: TD-1473 [Tablet B]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
Study: NCT02204189
Drug: TongFuSan
Approvals — FDA: no, EMA: no, PMDA: no
Description: TongFuSan 1g
Study: NCT00431418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT00207740
Drug: CNTO148
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
Study: NCT00207740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
Study: NCT00284856
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
Study: NCT00284856
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: montelukast 10 mg Pbo tablet once daily, 6 month treatment period
Study: NCT02357758
Drug: Antibiotic Prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approved clinical dosage or antibiotics
Study: NCT02499562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03353831
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28
Study: NCT03353831
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by intravenous route q14 during the treatment period
Study: NCT03277573
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
Study: NCT03277573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredient
Study: NCT04667897
Drug: 601 1.25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection (intravitreal use)
Study: NCT04667897
Drug: Ranibizuman 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection (intravitreal use)
Study: NCT02061657
Drug: Placebo( for misoprostol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
Study: NCT01551836
Drug: Paracetamol formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: formulation 1
Study: NCT01551836
Drug: Paracetamol formulation 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 2
Study: NCT01837043
Drug: Calcineurin Inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02213900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02730741
Drug: Lcr restituo® sachet
Approvals — FDA: no, EMA: no, PMDA: no
Description: symptomatic treatment of diarrhoea
Study: NCT02730741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00372385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT00210977
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
Study: NCT01777269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one capsule daily
Study: NCT00504881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
Study: NCT02967172
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01605331
Drug: sustained-release recombinant human GH (SR-rhGH)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02275936
Drug: N91115
Approvals — FDA: no, EMA: no, PMDA: no
Description: S Nitrosoglutathione Reductase Inhibitor
Study: NCT00695019
Drug: placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg matching placebo lozenges
Study: NCT01508000
Drug: FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU, folinic acid, oxaliplatin
Study: NCT01822288
Drug: Estradiol & medroxyprogesterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
Study: NCT03146390
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: all subjects will perform all interventions of all arms
Study: NCT03146390
Drug: Alcohol free essential oils
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: all subjects will perform all interventions of all arms
Study: NCT02658721
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If the patient had a VAS score of \>4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
Study: NCT02658721
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients with a VAS score of \>4 were administered with 75 mg diclofenac sodium via intramuscular route.
Study: NCT04463134
Drug: NTM drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTM drug treatment according to guideline and sensitivity test results
Study: NCT00879658
Drug: BAF312
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00879658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00866216
Drug: Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals
Normalized name: azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00866216
Drug: Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00128063
Drug: succinylated human serum albumin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01997658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
Study: NCT03578042
Drug: Losartan and amlodipine and hydrochlorothiazide
Normalized name: aliskiren, amlodipine and hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: this is a fixed combination containing the 3 drugs
Study: NCT03578042
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: any free triple combination therapy for hypertension given as 2 or 3 pills
Study: NCT01996644
Drug: Placebo vs Setraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01996644
Drug: Setraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg DCS
Study: NCT02205879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02219828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00151736
Drug: R-etodolac + chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-etodolac 600mg tablets + chlorambucil 2mg tablets
Study: NCT01878695
Drug: IV/oral n-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01637558
Drug: 8 hourly LPV/r during TB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 hourly LPV/r during TB treatment
Study: NCT00006126
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02658149
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 mg Epinephrine are injected as part of the drug cocktail
Study: NCT00171093
Drug: valsartan + simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00874796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
Study: NCT03532178
Drug: Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period.
Study: NCT00332189
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
Study: NCT00913653
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00867282
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00241939 750ug using inhaler A
Study: NCT00867282
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00241939 750ug using inhaler B
Study: NCT00395148
Drug: rHDL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01231516
Drug: GSK1349572 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo tablet once daily
Study: NCT02179918
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg q3wks, IV
Study: NCT00690235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180mg subcutaneous injections, twice daily
Study: NCT00343798
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02932150
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT02932150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT03451292
Drug: Albutein 20% Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.
Study: NCT02253940
Drug: BILR 355 - Treatment B (new tablet formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253940
Drug: BILR 355 - Treatment C (new capsule formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253940
Drug: BILR 355 - Treatment E (new capsule formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003261
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03366246
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: according randomized this side received placebo or active product
Study: NCT01631942
Drug: NNC172-2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation.
Study: NCT03424135
Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Normalized name: naproxen and diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
Study: NCT03424135
Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
Normalized name: naproxen and diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
Study: NCT04701502
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for COVID-19
Study: NCT03935828
Drug: Oral versus topical antibioitics
Normalized name: Betadine Antibiotic Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously described in two arms
Study: NCT02775617
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
Study: NCT00774111
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 50 mg in combination with Etravirine
Study: NCT01836653
Drug: l-LV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT01845220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% acetone
Study: NCT01096095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
Study: NCT01441778
Drug: NSS nasal irrigation salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal irrigation twice daily for 4 weeks period
Study: NCT03675178
Drug: Anerning particle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
Study: NCT01441778
Drug: BHS nasal irrigation salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal irrigation twice daily for 4 weeks period
Study: NCT03675178
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
Study: NCT00789061
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dosage/day/year
Study: NCT00510367
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 By Vein On Day 1
Study: NCT00510367
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 By Vein Over 72 Hours
Study: NCT02788591
Drug: Proton Pump Inhibitor (PPI) Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
Study: NCT00555347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02509403
Drug: Essential oils infused Perineal Hygiene wipe
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
Study: NCT00757367
Drug: TI Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
Study: NCT02042443
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02042443
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02203123
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02042443
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00133692
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04677868
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
Study: NCT02138916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously on study week 0 until study week 48 inclusive
Study: NCT03848481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution contains matching excipients.
Study: NCT00002790
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03310463
Drug: ETX2514SUL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
Study: NCT00084578
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02366377
Drug: SHR3824
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02366377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01860196
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01192178
Drug: FLOVENT™ DISKUS™ 100 mcg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
Study: NCT01192178
Drug: ADVAIR™ DISKUS™ 100/50 mcg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
Study: NCT01943617
Drug: Thymosin-α
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-viral and antitherapy
Study: NCT03180710
Drug: BioChaperone® Combo 75/25 at 0.6 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
Study: NCT03180710
Drug: BioChaperone® Combo 75/25 at 0.8 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
Study: NCT03180710
Drug: BioChaperone® Combo 75/25 at 1.0 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
Study: NCT03180710
Drug: Humalog® Mix25 at 0.8 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Humalog® Mix25 at 0.8 U/kg
Study: NCT00576511
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo o.d.
Study: NCT04433104
Drug: drug therapy according to Vietnamese MOHS procedure
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol, Terbutaline
Study: NCT01535014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)
Study: NCT03507374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
Study: NCT02208154
Drug: Selective Digestive Decontamination (SDD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDD consists of both:~* SOD (described elsewhere)~* AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)
Study: NCT00485160
Drug: Continuous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00485160
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00068523
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide IV over 1 hour on days -3 to -2